Why is Glenmark Pharma falling/rising?

As of 13-Oct, Glenmark Pharmaceuticals Ltd. is experiencing a decline in its stock price, currently at Rs 1,915.00, which reflects a decrease of Rs 24.25 or 1.25%. Today's price summary indicates that the stock has underperformed its sector by 1.1% and has fallen after two consecutive days of gains. The stock touched an intraday low of Rs 1,895.5, representing a drop of 2.26%. Over the past week, Glenmark has seen a return of -2.85%, and while it has generated a positive return of 6.67% over the past year, its recent performance contrasts with the significant profit increase of 254.3% and a favorable PEG ratio of 0.2. The company maintains a strong ability to service its debt with a low Debt to EBITDA ratio of 1.00 times and has high institutional holdings at 38.3%, which suggests confidence from larger investors.
In the broader market context, Glenmark's recent performance is notably weaker compared to the Sensex, which has gained 0.66% over the past week. This underperformance may be attributed to the stock's current trading position, as it is lower than its 5-day, 20-day, and 50-day moving averages, despite being above the 100-day and 200-day averages. The stock's liquidity remains adequate for trading, with a delivery volume increase of 184.92% against the 5-day average, indicating rising investor participation. However, the overall market sentiment appears to favor the benchmark index, which may be contributing to the stock's current decline.